Total Payments
$874,001
2024 Payments
$24,647
Companies
21
Transactions
659
Payment Breakdown by Category
Other$429,604 (49.2%)
Consulting$265,380 (30.4%)
Research$105,558 (12.1%)
Travel$60,764 (7.0%)
Food & Beverage$12,630 (1.4%)
Education$63.88 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $429,604 | 184 | 49.2% |
| Consulting Fee | $265,380 | 70 | 30.4% |
| Unspecified | $105,558 | 47 | 12.1% |
| Travel and Lodging | $60,764 | 148 | 7.0% |
| Food and Beverage | $12,630 | 208 | 1.4% |
| Education | $63.88 | 2 | 0.0% |
Payments by Type
General
$768,443
612 transactions
Research
$105,558
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $266,690 | 234 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $126,750 | 89 | $0 (2024) |
| Eli Lilly and Company | $109,527 | 92 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $62,979 | 39 | $0 (2024) |
| Kaneka Pharma America LLC | $50,379 | 6 | $0 (2021) |
| Novo Nordisk Inc | $46,768 | 29 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $44,851 | 36 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $42,072 | 25 | $0 (2024) |
| Lilly USA, LLC | $37,018 | 39 | $0 (2024) |
| ARALEZ PHARMACEUTICALS US INC. | $25,087 | 19 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,647 | 35 | Amgen Inc. ($7,166) |
| 2023 | $70,314 | 85 | Eli Lilly and Company ($33,382) |
| 2022 | $98,218 | 61 | Eli Lilly and Company ($54,763) |
| 2021 | $77,161 | 45 | Kaneka Pharma America LLC ($22,095) |
| 2020 | $192,076 | 78 | Amgen Inc. ($64,132) |
| 2019 | $90,469 | 81 | Amgen Inc. ($44,841) |
| 2018 | $136,697 | 108 | Amgen Inc. ($35,655) |
| 2017 | $184,419 | 166 | Amgen Inc. ($92,101) |
All Payment Transactions
659 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $76.78 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $610.55 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $425.80 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $191.52 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $52.48 | General |
| 11/15/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $26.51 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $25.06 | General |
| 11/15/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $22.77 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $14.89 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $9.99 | General |
| 11/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $8.04 | General |
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: DIABETES | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $462.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/18/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $107.26 | General |
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,720.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT | ||||||
| 09/13/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $73.79 | General |
| 05/31/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $327.37 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/16/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,308.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/14/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,308.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $8.10 | General |
| Category: Cardiology | ||||||
| 04/29/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 04/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $380.00 | General |
| Category: Diabetes | ||||||
| 04/17/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Cardiology | ||||||
| 04/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $36.49 | General |
| 04/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $63.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Evinacumb Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $35,418 | 8 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $20,452 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $16,981 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT | Eli Lilly and Company | $4,720 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $4,556 | 3 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $3,172 | 2 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $3,045 | 2 |
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS | Regeneron Pharmaceuticals, Inc. | $2,745 | 3 |
| CTQJ230A12001 | Novartis Pharmaceuticals Corporation | $2,528 | 2 |
| Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospec | Amgen Inc. | $2,310 | 1 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $2,294 | 1 |
| Trend Analysis of CV risk; Approval Rate and LLT Treatment Pattern of Pt Prescribed PCSK9i | Amgen Inc. | $1,878 | 2 |
| Characteristics of patients approved and denied access to PCSK9i therapy | Amgen Inc. | $1,131 | 2 |
| A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $1,082 | 5 |
| Geographic Disparities in LDL-C goal achievment in high risk CV patients | Amgen Inc. | $639.47 | 1 |
| EVINACUMB CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $586.40 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $560.01 | 1 |
| Efficacy and Safety of Alirocumab? | SANOFI US SERVICES INC. | $538.66 | 2 |
| CV Risks in Patients requesting access to PCSK9i and other LLT | Amgen Inc. | $423.61 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF VARYING DOSES AND DOSE REGIMENS OF EVINACUMAB IN PATIENTS WITH PERSISTENT HYPERCHOLESTEROLEMIA DESPITE MAXIMALLY TOLERATED LIPID MODIFYING THERAPY | Regeneron Pharmaceuticals, Inc. | $205.17 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $140.82 | 1 |
| PCSK9i Rejection Rates across patients with varying risk factors | Amgen Inc. | $52.50 | 1 |
| EX9536-4388 | Novo Nordisk AS | $50.00 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $48.50 | 1 |
About Dr. Seth Baum, MD
Dr. Seth Baum, MD is a Cardiovascular Disease healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649210121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seth Baum, MD has received a total of $874,001 in payments from pharmaceutical and medical device companies, with $24,647 received in 2024. These payments were reported across 659 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($429,604).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boca Raton, FL
- Active Since 06/07/2006
- Last Updated 10/14/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1649210121
Products in Payments
- Repatha (Biological) $259,035
- JARDIANCE (Drug) $164,985
- EVKEEZA (Biological) $49,157
- LIPOSORBER (Device) $42,254
- PRALUENT ALIROCUMAB INJECTION (Biological) $22,471
- LEQVIO (Drug) $16,084
- Ozempic (Drug) $15,852
- ZONTIVITY (Drug) $13,794
- PRALUENT (Drug) $11,540
- YOSPRALA (Drug) $11,293
- NEXLIZET (Drug) $11,280
- Victoza (Drug) $10,886
- PELACARSEN (Drug) $8,910
- NO PRODUCT DISCUSSED (Drug) $7,064
- UBRELVY (Drug) $6,338
- FARXIGA (Drug) $1,074
- LUX-Dx Insertable Cardiac Monitor (Device) $132.99
- STEGLATRO (Drug) $127.04
- NEXLETOL (Drug) $107.27
- Corlanor (Drug) $83.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boca Raton
David Funt, M.d, M.D
Cardiovascular Disease — Payments: $150,344
Cardiovascular Disease $150,344
Robert Ullman, Md, MD
Cardiovascular Disease — Payments: $40,434
Cardiovascular Disease $40,434
Dr. Aaron Bush, Md, MD
Cardiovascular Disease — Payments: $32,654
Cardiovascular Disease $32,654
Dr. Barry Merrill, Md, MD
Cardiovascular Disease — Payments: $29,164
Cardiovascular Disease $29,164
Dr. Andrew Panakos, M.d, M.D
Cardiovascular Disease — Payments: $19,328
Cardiovascular Disease $19,328
Mark Rubenstein, M.d, M.D
Cardiovascular Disease — Payments: $17,003
Cardiovascular Disease $17,003